Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.07M | 5.96M | 5.17M | 5.82M | 4.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.63M | 19.08M | 14.76M | 16.59M | 14.12M |
| Operating Income | -19.63M | -19.08M | -14.76M | -16.59M | -14.12M |
| Income Before Tax | -17.78M | -17.31M | -13.26M | -14.96M | -11.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.78M | -17.31M | -13.26M | -14.96M | -11.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.78M | -17.31M | -13.26M | -14.96M | -11.91M |
| EBIT | -19.63M | -19.08M | -14.76M | -16.59M | -14.12M |
| EBITDA | -19.54M | -18.99M | -14.67M | -16.49M | -14.04M |
| EPS Basic | -0.31 | -0.38 | -0.31 | -0.35 | -0.29 |
| Normalized Basic EPS | -0.19 | -0.23 | -0.20 | -0.22 | -0.18 |
| EPS Diluted | -0.31 | -0.38 | -0.31 | -0.35 | -0.29 |
| Normalized Diluted EPS | -0.19 | -0.23 | -0.20 | -0.22 | -0.18 |
| Average Basic Shares Outstanding | 57.54M | 46.04M | 42.27M | 42.27M | 40.71M |
| Average Diluted Shares Outstanding | 57.54M | 46.04M | 42.27M | 42.27M | 40.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |